Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Insight - Can ageing be slowed to prevent disease?

This article was originally published in Scrip

Executive Summary

The idea of extending the human lifespan has long fascinated the public and challenged scientists. Funding for research into ageing processes, and the R&D of therapeutics to slow them, is increasing. Recent findings suggest that progress has been made, motivated in part by the rapid growth of elderly populations that might benefit from such advances. Furthermore, economists predict that many countries may face bankruptcy by 2050 (or earlier) because of rising healthcare expenditures associated with care of the elderly.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel